Publications

Click here to download a PDF listing all COG Developmental Therapeutics Publications.

2016

2016

ADVL0813 - Cixutumumab (IMC-A12) + Temsirolimus (CCI-779)
Mizuno T, Fukuda T, Christians U, Perentesis JP, Fouladi M, Vinks AA. Population pharmacokinetics of temsirolimus and sirolimus in children with recurrent solid tumors: a report from the Children's Oncology Group. Br J Clin Pharmacol. 2016 Nov; Epub ahead of print. PMID: 28000286. PMCID: PMC Journal - In Process.

ADVL1115 - Trebananib (AMG386) Abstract
Abdelrahman RA, Leary SE, Reid JM, Minard CG, Fox E, Weigel BJ. Population Pharmacokinetic model of trebananib in pediatric patients with relapsed solid tumors. In: Proceedings of the American Conference on Pharmacometrics 2016 (ACoP7). J Pharmacokinet Pharmacodyn; 2016 Oct; 43(1 suppl):abstr 3583429.

ADVL1314 - Eribulin Mesylate (E7389) Abstract
Schafer ES, Rau RE, Liu X, Minard CG, D'Adamo DR, Scott R, Reyderman L, Martinez GV, Fox E, Weigel BJ, Blaney SM. A phase 1 study of eribulin mesylate (E7389), a novel microtubule targeting chemotherapeutic agent in children with refractory or recurrent solid tumors (excluding CNS), including lymphomas: a Children’s Oncology Group Phase 1 Consortium study (ADVL1314). 2016 ASCO Annual Meeting. J Clin Oncol; 2016 May; 34(suppl):abstr 2567.

ADVL1315 - Axitinib Abstract
Geller JI, Fox E, Turpin BK, Reid JM, Liu X, Minard CG, Goldstein SL, Weigel BJ. ADVL1315: A phase 1 study of the VEGF receptor tyrosine kinase inhibitor axitinib (INLYTA, IND# 123101) in children with recurrent or refractory solid tumors—A Children's Oncology Group study. 2016 ASCO Annual Meeting. J Clin Oncol; 2016 May; 34(suppl):abstr 10558.

ADVL1411 - Talazoparib (BMN 673) Abstract
Schafer ES, Rau RE, Liu X, Minard CG, Reid JM, Fox E, Weigel BJ, Blaney SM. A phase 1/2 study of talazoparib (BMN 673), an oral poly(ADP-ribose) polymerase inhibitor, plus temozolomide in children with refractory or recurrent malignancies: A Children's Oncology Group Phase 1 Consortium study (ADVL1411). Poster presented at: Proceedings of the 28th EORTC-NCI-AACR Molecular Targets and Cancer Therapeutics Symposium. 2016 Nov 29 - Dec 2; Munich, Germany. AACR; 2016.

DVL Biostatistics Abstract
Minard CG, Seibel NL, Berg SL, Fox E, Weigel BJ. Impact of the Pediatric Central Institutional Review Board (PedCIRB) in Children's Oncology Group Phase 1 Consortium dose escalation studies. 2016 ASCO Annual Meeting. J Clin Oncol; 2016 May; 34(suppl):abstr e18050.

2015

2015

ADVL1011 – Ruxolitinib
Loh ML, Tasian SK, Rabin KR, Brown PA, Magoon D, Reid JM, Chen X, Ahern CH, Weigel BJ, Blaney SM. A phase 1 dosing study of ruxolitinib in children with relapsed or refractory solid tumors, leukemias, or myeloproliferative neoplasms: A Children's Oncology Group phase 1 consortium study (ADVL1011). Pediatr Blood Cancer. 2015 May 13 [Epub ahead of print]. PMCID: PMC Journal - In Process.

ADVL1014 – Reolysin
Kolb EA, Sampson V, Stabley D, Walter A, Sol-Church K, Cripe T, Hingorani P, Ahern CH, Weigel BJ, Zwiebel J, Blaney SM. A phase I trial and viral clearance study of reovirus (Reolysin) in children with relapsed or refractory extra-cranial solid tumors: a Children's Oncology Group Phase I Consortium report. Pediatr Blood Cancer. 2015 May;62(5):751-8. PMCID: PMC4376570.

ADVL0911 – Seneca Valley Virus (NTX-010)
Burke MJ, Ahern CH, Weigel BJ, Poirier JT, Rudin CM, Chen Y, Cripe TP, Bernhardt M, Blaney SM. Phase 1 trial of seneca valley virus (NTX-010) in children with relapsed / refractory solid tumors: A report of the Children's Oncology Group. Pediatr Blood Cancer. 2015 May;62(5):743- 50. PMCID: PMC4376652.

ADVL0813 – Cixutumumab (IMC-A12) + Temsirolimus (CCI-779)
Fouladi M, Perentesis JP, Wagner LM, Vinks AA, Reid JM, Ahern CH, Thomas G, Mercer C, Krueger DA, Houghton PJ, Doyle A, Chen H, Weigel BJ, Blaney SM. A Phase I study of cixutumumab (IMC-A12) in combination with temsirolimus (CCI-779) in children with recurrent solid tumors: A Children's Oncology Group Phase 1 Consortium report. Clin Cancer Res. 2015 Apr 1;21(7):1558-65. PMCID: PMC4454739.

ADVL1114 – Temsirolimus (CCI-779) with Intensive Re-induction Abstract
Rheingold S, Whitlock J, Tasian S, Teachey D, Borowitz M, Liu X, Ahern CH, Minard CG, Fox E, Weigel BJ, Blaney SM. Temsirolimus and intensive re-induction chemotherapy for 2nd or greater relapse of acute lymphoblastic leukemia (ALL): a Children’s Oncology Group study. 2015 ASCO Annual Meeting. J Clin Oncol; 33(15s): abstr 10029.

ADVL1212 – Crizotinib with Conventional Chemotherapy Abstract
Greengard E, Mosse Y, Liu X, Ahern CH, Minard CG, Blaney SM, Fox E, Weigel BJ. A Safety and tolerability of crizotinib in combination with chemotherapy for relapsed or refractory solid tumors or anaplastic large cell lymphoma: a Children’s Oncology Group phase I consortium study. 2015 ASCO Annual Meeting. J Clin Oncol; 33(15s): abstr 10058. 

ADVL1213 – Ontuxizumab (MORAb-004) Abstract
Norris RE, Fox E, Reid JM, Ralya AT, Liu X, Ahern CH, Minard CG, Dahl J, Eubank R, Weigel BJ. Phase I trial of ontuxizumab (MORAb-004) in children with relapsed or refractory solid tumors: A Children’s Oncology Group Study. 2015 ASCO Annual Meeting. J Clin Oncol; 33(15s): abstr 10036.

AHOD1221 – Brentuximab Vedotin + Gemcitabine Abstract
Cole PD, Metzger M, Drachtman RA, Horton TM, Liu X, Ahern CH, Minard CG, Fox E, Blaney SM, Weigel BJ, Kelly K. Phase 1 trial of brentuximab vedotin in combination with gemcitabine for pediatric and young adult patients with relapsed or refractory Hodgkin lymphoma, a Children’s Oncology Group report. 2015 ASCO Annual Meeting. J Clin Oncol; 33(15s): abstr 8544.

2014

2014

ADVL0918 – Temsirolimus + Irinotecan and Temozolomide
Bagatell R, Norris R, Ingle AM, Ahern C, Voss S, Fox E, Little AR, Weigel BJ, Adamson PC, Blaney S. Phase 1 trial of temsirolimus in combination with irinotecan and temozolomide in children, adolescents and young adults with relapsed or refractory solid tumors: A children's oncology group study. Pediatr Blood Cancer. 2014 May;61(5):833-9. PMCID: PMC4196713.

ADVL1013 – MK-2206
Fouladi M(1), Perentesis JP, Phillips CL, Leary S, Reid JM, McGovern RM, Ingle AM, Ahern CH, Ames MM, Houghton P, Doyle LA, Weigel B, Blaney SM. A phase I trial of MK-2206 in children with refractory malignancies: A children's oncology group study. Pediatr Blood Cancer. 2014 Jul;61(7):1246-51. PMCID: PMC4456022.

ADVL1011 – Ruxolitinib Abstract
Tasian SK, Loh ML, Rabin KR, Brown PA, Ahern CH, Weigel BJ, Blaney SM. A Phase I Study of Ruxolitinib in Children with Relapsed/Refractory Solid Tumors, Leukemias, or Myeloproliferative Neoplasms: A Children’s Oncology Group Phase I Consortium Study (ADVL1011). 2014 ASCO Annual Meeting. J Clin Oncol; 32(5s): abstr 10019.

ADVL1111 – Tivantinib (ARQ 197) Abstract
Geller J, Perentesis JP, Ahern CH, Kudgus RA, Reid JM, Fox E, Blaney SM, Weigel BJ. A Phase 1 Study of the c-Met Inhibitor, Tivantinib (ARQ 197, IND#112603) in Children with Relapsed or Refractory Solid Tumors: A Children’s Oncology Group Study. 2014 ASCO Annual Meeting. J Clin Oncol; 32(5s): abstr 2627.

ADVL1211 – Cabozantinib (XL184) Abstract
Chuk MK, Widemann BC, Ahern CH, Reid JM, Kim A, Wright JJ, Lodish MB, Fox E, Weigel BJ, Blaney SM. A phase I study of Cabozantinib (XL184) in children and adolescents with recurrent or refractory solid tumors, including CNS tumors: A Children’s Oncology Group Phase I Consortium Trial. 2014 ASCO Annual Meeting. J Clin Oncol; 32(5s): abstr 10078.

2013

2013

ADVL1112 – Imetelstat
Thompson PA, Drissi R, Muscal J, Panditharatna EA, Fouladi M, Ingle AM, Ahern CH, Reid JM, Lin T, Weigel BJ, Blaney SM. A Phase 1 trial of imetelstat in children with refractory or recurrent solid tumors: A Children's Oncology Group Phase 1 Consortium study (ADVL1112). 2013 Dec 1;19(23):6578-6584. PMCID: PMC4079262.

ADVL0912 – Crizotinib
Mossé YP, Lim MS, Voss SD, Wilner K, Ruffner K, Laliberte J, Rolland D, Balis, F, Maris JM, Weigel BJ, Ingle AM, Ahern CH, Adamson PC, Blaney SM. Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study. Lancet Oncol; 2013 May; 14(6):472-480. PMCID: PMC3730818.

ADVL0819 – Vorinistat and Temozolomide in CNS Tumors
Hummel, T.R., Wagner, L, Ahern, C., Fouladi, M., Reid, J.M., McGovern, R.M., Ames, M.M., Gilbertson, R.J., Horton, T., Ingle, A.M., Weigel, B., Blaney, S.M. A pediatric phase 1 trial of vorinostat and temozolomide in relapsed or refractory brain or spinal cord tumors: a Children’s Oncology Group Phase 1 Consortium study. Pediatr Blood Cancer; 2013 Sep; 60(9):1452-1457. PMCID: PMC4139006.

ADVL0815 – Pazopanib
Bender, J.G., Lee, A., Reid, J.M., Baruchel, S., Roberts, T., Voss, S., Wu, B., Ahern, C., Ingle, A.M., Harris, P., Weigel, B., Blaney, S.M. A phase 1 pharmacokinetic and pharmacodynamics study of pazopanib in children with refractory solid tumors including soft tissue sarcoma: a Children’s Oncology Group Phase 1 Consortium study. J Clin Oncol; 2013 Aug; 31(24):3034-3043. PMCID: PMC3739862.

ADVL0911 – Seneca Valley Virus (NTX-010) Abstract
Burke MJ, Ahern CH, Weigel BJ, Ingle AM, Cripe TP, Bernhardt M, Blaney SM. A phase I study of seneca valley virus (NTX-010) in children with relapsed/refractory solid tumors (ADVL0911): A report of the Children's Oncology Group. Presented at: The Seventh International Meeting On Replicating Oncolytic Virus Therapeutics; 2013 June 15-18; Montreal, Canada.

ADVL1014 – Reolysin Abstract
Kolb EA, Sampson V, Stabley D, Walter A, Cripe TP, Hingorani P, Ahern CH, Ingle AM, Weigel BJ, Blaney SM. A Phase I trial and Viral Clearance Study of Reovirus (Reolysin) in Children with Relapsed or Refractory Extra-cranial Solid Tumors: A Children’s Oncology Group Phase I Consortium Report. Poster presented at: AACR-Pediatric Cancer at the Crossroads: Translating Discovery Into Improved Outcomes Conference; 2013 November 3-6; San Diego, CA.

ADVL1115 – Trebananib (AMG386) Abstract
Leary SE, Park JR, Reid JM, Ralya A, Baruchel S, Wu B, Ingle AM, Ahern CH, Weigel BJ, Blaney SM. A phase I trial and pharmacokinetic study of trebananib (AMG386) in children with recurrent or refractory solid tumors: A Children’s Oncology Group Phase 1 Consortium report. 2013 ASCO Annual Meeting. J Clin Oncol; 2013 May; 31(15 suppl):abstr 2538.

2012

2012

ADVL0916 - Vorinostat and Bortezomib
Muscal J, Horton TM, Ingle AM, Ahern CH, McGovern R, Reid JM, Ames MM, Espinoza- Delgado I, Weigel BJ, Blaney SM. A phase I trial of vorinostat and bortezomib in children with refractory or recurrent solid tumors: A Children's Oncology Group phase 1 consortium study (ADVL0916). Pediatr Blood Cancer; 2012 Nov; 60(3):390-395. PMCID: PMCID3511610.

ADVL0812 - MLN8237
Mossé, YP, Lipsitz EG, Teachey DT, Maris JM, Weigel BJ, Adamson PC, Ingle AM, Ahern CH, Blaney SM. Pediatric phase 1 trial and pharmacokinetic study of MLN8237, an investigational oral selective small molecule inhibitor of aurora kinase A: A Children's Oncology Group Phase 1 Consortium study. Clin Cancer Res; 2012 Nov; 18(21):6058-6064. PMCID: PMC4008248.

ADVL0714 - VEGF Trap
Glade Bender JL, Blaney SM, Borinstein SC, Reid JM, Baruchel S, Ahern CH, Ingle AM, Yamashiro DJ, Chen A, Weigel BJ, Adamson PC, Park JR. A phase I trial and pharmacokinetic study of aflibercept (VEGF Trap) in children with refractory solid tumors: A Children’s Oncology Group Phase I consortium report. Clin Cancer Res; 2012 Sep; 18(18):5081-5089. PMCID: PMC3445751.

ADVL0712 – Cixutumumab (IMC-A12)
Malempati S, Weigel BJ, Ingle AM, Ahern CH, Carroll JM, Roberts CT, Reid JM, Schmechel S, Voss SD, Cho SY, Chen HX, Krailo M, Adamson PC, Blaney SM. Phase I/II trial and pharmacokinetic study of cixutumumab in pediatric patients with refractory solid tumors and ewing sarcoma: A report from the Children's Oncology Group. J Clin Oncol; 2012 Jan; 30(3):256-262. PMCID: PMC3269952.

ADVL0612 – Sunitinib Pharmacokinetics
DuBois SG, Shusterman S, Reid JM, Ingle AM, Ahern CH, Baruchel S, Glade Bender JL, Ivy SP, Adamson PC, Blaney SM, DuBois JJ. Tolerability and pharmacokinetic profile of a sunitinib powder formulation in pediatric patients with refractory solid tumors: A Children's Oncology Group study. Cancer Chemother Pharmacol; 2012 Apr; 69(4):1021-1027. PMCID: PMC3149978.

ADVL0413 – Sorafenib
Widemann BC, Kim A, Fox E, Baruchel S, Adamson PC, Ingle AM, Glade Bender JL, Burke MJ, Weigel BJ, Stempak D, Balis FM, Blaney SM. A Phase I trial and pharmacokinetic study of sorafenib in children with refractory solid tumors or refractory leukemias: A Children's Oncology Group Phase I Consortium report. Clin Cancer Res; 2012 Nov; 18(21):6011-6022. PMCID: PMC4008314.

ADVL1013 – MK 2206 Abstract
Phillips C, Fouladi M, Perentesis JP, Leary SE, McGovern R, Reid JM, Ingle AM, Ahern CH, Ames MM, Houghton PJ, Doyle A, Weigel BJ, Blaney SM. A phase I trial of MK 2206 in children with refractory solid tumors: A Children's Oncology Group study. 2012 ASCO Annual Meeting. J Clin Oncol; 2012 May; 30(15 suppl):abstr 9581.

ADVL0918 – Temsirolimus + Irinotecan and Temozolomide Abstract
Bagatell R, Norris RE, Ingle AM, Ahern CH, Saggio JN, Little AR, Weigel BJ, Blaney SM. Phase I trial of temsirolimus (TEM), irinotecan (IRN), and temozolomide (TMZ) in children with refractory solid tumors: A Children's Oncology Group study. 2012 ASCO Annual Meeting. J Clin Oncol; 2012 May; 30(15 suppl):abstr 9540.

ADVL0912 – Crizotinib Abstract
Mossé, YP, Balis FM, Lim MS, Blaney SM, Voss SD, Fox EJ, Bagatell R, Weigel BJ, Adamson PC, Ingle AM, Ahern CH, Laliberte J. Efficacy of crizotinib in children with relapsed/refractory ALK-driven tumors including anaplastic large cell lymphoma and neuroblastoma: A Children's Oncology Group phase I consortium study. 2012 ASCO Annual Meeting. J Clin Oncol; 2012 May; 30(15 suppl):abstr 9500.

ADVL0813 – Cixutumumab (IMC-A12) + Temsirolimus Abstract
Fouladi M, Perentesis JP, Wagner LM, Ingle AM, Thomas GA, Krueger DA, Houghton P, Vinks AA, Doyle LA, Weigel BJ, Blaney SM. A phase I trial of IMC A12 and temsirolimus in children with refractory solid tumors: A Children’s Oncology Group study. 2012 ASCO Annual Meeting. J Clin Oncol; 2012 May; 30(15 suppl):abstr 9541.

2011

2011

ADVL0612 - Sunitinib
DuBois SG, Shusterman S, Ingle AM, Ahern CH, Reid JM, Wu B, Baruchel S, Glade Bender JL, Ivy SP, Grier HE, Adamson PC, Blaney SM. Phase I and pharmacokinetic study of sunitinib in pediatric patients with refractory solid tumors: A Children’s Oncology Group study. Clin Cancer Res; 2011 Aug; 17(15):5113-5122. PMCID: PMC3149978.

ADVL0516 – Dasatinib
Aplenc R, Blaney S, Strauss LC, Balis FM, Shusterman S, Ingle AM, Agrawal S, Sun J, Wright J, Adamson PC. Pediatric phase I trial and pharmacokinetic study of dasatinib: A report from the Children's Oncology Group Phase I Consortium. J Clin Oncol; 2011 Mar; 29(7):839-844. PMCID: PMC3068059.

ADVL0516 – Dasatinib Correlative study
Guerrouahen BS, Wieder E, Blanchard EG, Lee FY, Aplenc R, Corey S. Flow Cytometric Determination of Src Phosphorylation in Pediatric Patients Treated With Dasatinib. Pediatr Blood Cancer; 2009 Dec; 53(6):1132-1135. PMCID: PMC2760231.

ADVL0515 –Vinblastine + Carboplatin in Low Grade Glioma
Jakacki RI, Bouffet E, Adamson PC, Ingle AM, Voss SD, Blaney SM. A Phase I Study Of Vinblastine In Combination With Carboplatin For Children With Low-Grade Gliomas: A Children’s Oncology Group Phase 1 Consortium Study. Neuro-oncol; 2011 Aug; 13(8):910-915. PMCID: PMC3145477.

ADVL0419 – Valproic Acid
Su JM, Li X, Thompson PA, Ou C, Ingle AM, Russell HV, Lau CC, Adamson PC, Blaney SM. Phase 1 study of valproic acid in pediatric patients with refractory solid or CNS tumors: A Children's Oncology Group report. Clin Cancer Res; 2011 Feb; 17(3):589-597. PMCID: PMC3064523.

ADVL0319 – Lenalidomide
Berg S, Cairo M, Russell HV, Ayello J, Ingle AM, Lau H, Chen N, Adamson P, Blaney S. Safety, pharmacokinetics and immunomodulatory effects of lenalidomide in children and adolescents with relapsed/refractory solid tumors or myelodysplastic syndrome: A Children's Oncology Group Phase I Consortium report. J Clin Oncol; 2011 Jan; 29(3):316-323. PMCID: PMC3056465.

ADVL0116 – Tipifarnib
Widemann B, Arceci R, Jayaprakash N, Fox E, Zannikos P, Goodspeed W, Goodwin A, Wright J, Blaney S, Adamson P, Balis F. Phase 1 trial and pharmacokinetic study of the farnesyl transferase inhibitor tipifarnib in children and adolescents with refractory leukemias: A report from the Children’s Oncology Group. Pediatr Blood Cancer; 2011 Feb; 56(2):226-233.

PMCID: PMC3271115.

ADVL0916 – Vorinostat and Bortezomib Abstract
Muscal J, Thompson PA, Horton TM, Ingle AM, Ahern CH, McGovern R, Reid JM, Ames MM, Weigel BJ, Blaney SM. A phase I trial of vorinostat and bortezomib in children with refractory or recurrent solid tumors: A Children's Oncology Group study. 2011 ASCO Annual Meeting. J Clin Oncol; 2011 May; 29(15 suppl):abstr 9522.

ADVL0819 – Vorinostat and Temozolomide Abstract
Hummel TR, Wagner LM, Ahern CH, McGovern R, Ames MM, Gilbertson RJ, Horton TM, Ingle AM, Weigel BJ, Blaney SM. A pediatric phase I trial of vorinostat and temozolomide in relapsed or refractory primary brain or spinal cord tumors: A Children’s Oncology Group Phase I Consortium Study. 2011 ASCO Annual Meeting. J Clin Oncol; 2011 May; 29(15 suppl):abstr 9579.

ADVL0815 – Pazopanib Abstract
Glade Bender JL, Lee A, Adamson PC, Ingle AM, Ahern CH, Wu B, Baruchel S, Harris PJ, Ames MM, Weigel BJ, Blaney SM. Phase I study of pazopanib in children with relapsed or refractory solid tumors (ADVL0815): A Children's Oncology Group Phase I Consortium Trial. 2011 ASCO Annual Meeting. J Clin Oncol; 2011 Jun; 29(15 suppl):abstr 9501.

ADVL0815 – Pazopanib Abstract
Glade Bender JL, Khrichenko D, Voss SD, Lee A, Ingle AM, Ahern CH, Weigel BJ, Blaney SM, Roberts T. An expanded imaging cohort of pazopanib in children and adolescents with relapsed or refractory soft tissue sarcoma (ADVL0815): A Children's Oncology Group phase I consortium trial. In: Proceedings of the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics; 2011 Nov 12-16; San Francisco, CA. Mol Cancer Ther; 2011 Nov; 10(11 suppl):abstr nr C108.

ADVL0813 – Cixutumumab (IMC-A12) + Temsirolimus Abstract
Fouladi M, Perentesis JP, Wagner LM, Ingle AM, Gammon J, Thomas G, Krueger DA, Houghton P, Vinks S, Weigel BJ, Blaney S. A phase I trial of IMC-A12 and temsirolimus in children with refractory solid tumors: A Children's Oncology Group Study. 2011 ASCO Annual Meeting. J Clin Oncol; 2011 May; 29(15 suppl):abstr 9520.

ADVL0612 – Sunitinib Abstract
DuBois SG, Shusterman S, Reid JM, Ingle AM, Ahern CH, Baruchel S, Glade-Bender J, Ivy P, Grier H, Adamson PC, Blaney SM. Tolerability and Pharmacokinetic Profile of Sunitinib Given as a Powder Formulation to Children with Refractory Solid Tumors: A Children’s Oncology Group Study. In: 43rd Congress of the International Society of Paediatric Oncology (SIOP) 2011 Auckland, New Zealand, 28th–30th October, 2011, SIOP Abstracts. Pediatr Blood Cancer; 2011 Nov; 57(5): 717-718, Oral Presentation #O042.

Phase 1 Correlatives Studies - Antiangiogenesis Biomarkers Abstract
Baruchel S, Wu B, Mokhtari RB, Glade Bender JL, DuBois SG, Widemann BC, Park JR, Stempak D, Ahern CH, Weigel BJ. Surrogate biomarkers of antiangiogenesis in Children's Oncology Group (COG) phase I trials. 2011 ASCO Annual Meeting. J Clin Oncol; 2011 May; 29(15 suppl):abstr 9502.

2010

2010

ADVL0812 - MLN8237 Correlative Study
Lipsitz EG, Moorthy G, Fox E, Adamson PC. A sensitive and selective liquid chromatography/tandem mass spectrometry method for determination of MLN8237 in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci; 2010 Sep; 878(25):2369-2373. PMCID: PMC2940716.

ADVL0517 – Ispenisib
Souid A, Dubowy R, Ingle AM, Conlon MG, Sun J, Blaney S, Adamson P. A Pediatric Phase 1 Trial and Pharmacokinetic Study of Ispinesib: A Children’s Oncology Group Phase I Consortium Study. Pediatr Blood Cancer; 2010 Dec; 55(7):1323-1328. PMCID: PMC3053384.

ADVL0416 – Vorinostat
Fouladi M, Park J, Stewart CF, Gilbertson RJ, Schaiquevich P, Sun J, Reid JM, Ames MM, Speights R, Ingle AM, Zweibel J, Blaney S, Adamson P. Pediatric Phase I Trial and Pharmacokinetic Study of Vorinostat: A Children's Oncology Group Phase 1 Consortium Report. J Clin Oncol; 2010 Aug; 28(22):3623-3629. PMCID: PMC2917318.

ADVL0414 – Vincristine + Irinotecan + Temozolomide
Wagner LM, Perentesis JP, Reid JM, Ames MM, Safgren SL, Nelson, Jr. MD, Ingle AM, Blaney S, Adamson P. Phase I trial of two schedules of vincristine, oral irinotecan, and temozolomide (VOIT) for children with relapsed or refractory solid tumors: A Children's Oncology Group phase I consortium study. Pediatr Blood Cancer; 2010 Apr; 54(4):538-545. PMCID: PMC3074342.

ADVL0215 – Decitabine + Doxorubicin and Cyclophosphamide
George RE, Lahti J, Zhu K, Finkelstein D, Ingle AM, Reid JM, Krailo M, Neuberg D, Adamson P, Blaney S, Diller L. Phase I study of decitabine with doxorubicin and cyclophosphamide in children with neuroblastoma and other solid tumors: A children's oncology group study. Pediatr Blood Cancer; 2010 Oct; 55(4):629-638. PMCID: PMC3025700.

ADVL08N1 - Participation in Pharmacokinetic Studies
Berg S, Winick N, Ingle AM, Adamson P, Blaney S. Reasons for Participation in Optional Pharmacokinetic Studies in Children with Cancer: A Children’s Oncology Group Phase 1 Consortium Study. Pediatr Blood Cancer; 2010 Jul; 55(1):119-122. PMCID: PMC2911979.

P9423 – Valspodar (PSC833)
O'Brien MM, Lacayo N, Lum BL, Kshirsagar S, Buck S, Ravindranath Y, Bernstein M, Weinstein H, Chang M, Arceci R, Sikic BI, Dahl G. Phase I study of valspodar (PSC-833) with mitoxantrone and etoposide in refractory and relapsed pediatric acute leukemia: A report from the Children’s Oncology Group. Pediatr Blood Cancer; 2010 May; 54(5):694-702. PMCID: PMC2838930.

ADVL0812 - MLN8237 Abstract
Mossé, YP, Lipsitz EG, Maris JM, Weigel BJ, Adamson PC, Ingle AM, Ahern CH, Blaney SM. Pediatric phase 1 trial and pharmacokinetic study of MLN8237, an oral selective small molecule inhibitor of aurora kinase A: a Children’s Oncology Group phase 1 consortium study. 2010 ASCO Annual Meeting. J Clin Oncol 28:15s, 2010. (suppl; abstract 9529).

ADVL0714 - VEGF Trap Abstract
Park JR, Hawkins DS, Ingle AM, Borinstein SC, Bender JG, Yamashiro D, Baruchel S, Chen AR, Adamson PC, Blaney SM. A pediatric phase I trial and pharmacokinetic study of aflibercept (VEGF Trap): A Children's Oncology Group Phase I Consortium study. In: 2010 ASCO Annual Meeting Proceedings (Post-Meeting Edition). 2010 ASCO Annual Meeting. J Clin Oncol; 2010 May; 28(15s):abstr 9530.

ADVL0515 - Vinblastine + Carboplatin Abstract
Jakacki RI, Bouffet E, Ingle AM, Krailo M, Voss SD, Adamson PC, Blaney SM. Phase I study of vinblastine in combination with carboplatin for children with newly diagnosed and recurrent low-grade gliomas: Results of COG ADVL0515. In: Abstracts from the 14th International Symposium on Pediatric Neuro-Oncology; 2010 Jun 20-23; Vienna, Austria. Oxford (England): Oxford University Press; 2010. p. ii1-ii34. Neuro-oncol; 2010 Jun; 12(6): ii12, HGG.10.

2009

2009

ADVL0415 – Oxaliplatin and Irinotecan
McGregor LM, Spunt SL, Furman WL, Stewart CF, Schaiquevich P, Krailo M, Speights R, Ivy P, Adamson P, Blaney S. Phase 1 study of oxaliplatin and irinotecan in pediatric patients with refractory solid tumors: a children's oncology group study. Cancer; 2009 Apr; 115(8):1765-1775. PMCID: PMC2897817.

A0935 – ch14.18 + GM-CSF and IL-2
Gilman A, Ozkaynak F, Matthay KK, Krailo M, Yu A, Gan J, Sternberg A, Hank JA, Seeger R, Reaman GH, Sondel P. Phase I Study of ch14.18 with with Granulocyte-Macrophage Colony-Stimulating Factor and Interleukin-2 in Children with Neuroblastoma After Autologous Bone Marrow Transplant or Stem Cell Rescue: A Report From The Children’s Oncology Group. J Clin Oncol; 2009 Jan; 27(1):85-91. PMCID: PMC2645092.

P9973 (POG-9973) – Imantinib Pharmacokinetics
Menon-Andersen D, Mondick J, Jayaraman B, Thompson PA, Blaney S, Bernstein M, Bond M, Champagne MA, Fossler MJ, Barrett JS. Population pharmacokinetics of imatinib mesylate and its metabolite in children and young adults: A report from the Children's Oncology Group. Cancer Chemother Pharmacol; 2009 Jan; 63(2):229-238. PMID 18398615.

P9376 (POG 9376) – Taxol (Paxlitaxel) and Ifosfamide
Geller JI, Wall D, Perentesis J, Blaney S, Bernstein M. Phase I study of Paclitaxel with standard dose Ifosfamide in children with refractory solid tumors: a Pediatric Oncology Group study (POG 9376). Pediatr Blood Cancer; 2009 Mar; 52(3):346-350. PMCID: PMC2744894.

ADVL0712 – Cixutumumab (IMC-A12) Abstract
Malempati S, Weigel BJ, Ingle AM, Ahern CH, Carroll JM, Roberts CT, Fox F, Voss SD, Adamson P, Blaney S. A Phase I Trial and pharmacokinetic study of IMC-A12 in pediatric patients with relapsed/refractory solid tumors: A Children's Oncology Group Phase 1 Consortium study. 2009 ASCO Annual Meeting. J Clin Oncol; 2009 May; 27(15S):abstr 10013.

ADVL0414 – Vincristine + Irinotecan + Temozolomide Abstract
Wagner LM, Perentesis J, Reid JM, Ames MM, Safgren SL, Nelson, Jr. MD, Ingle AM, Blaney S, Adamson P. Phase I Trial and pharmacokinetic study of two schedules of vincristine, oral irinotecan, and temozolomide (VOIT) for children with refractory solid tumors: A Children's Oncology Group Phase 1 Consortium Study. 2009 ASCO Annual Meeting. J Clin Oncol; 2009 May; 27(15S):abstr 10017.

ADVL0414 – Vincristine + Irinotecan + Temozolomide Abstract
Wagner LM, Perentesis J, Reid JM, Ames MM, Safgren SL, Nelson, Jr. MD, Ingle AM, Blaney S, Adamson P. Phase I Trial of two Schedules of Vincristine, Oral Irinotecan, and Temozolomide (VOIT Regimen) for Children with Refractory Solid Tumors: a Children’s Oncology Group Phase I Consortium Study. Presented at: CTOS 15th Annual Meeting. Proceedings of the 2009 Connective Tissue Oncology Society Annual Meeting; 2009 Nov 5-7; Miami Beach, FL.

ADVL0413 – Sorafenib Abstract
Widemann B, Fox E, Adamson P, Baruchel S, Kim A, Ingle AM, Bender JG, Stempak D, Balis F, Blaney S. Phase I Study of Sorafenib in Children with Refractory Solid Tumors: A Children's Oncology Group Phase I consortium Trial. 2009 ASCO Annual Meeting. J Clin Oncol; 2009 May; 27(15S):abstr 10012.

ADVL0319 – Lenalidomide Abstract
Berg S, Russell HV, Cairo M, Ingle AM, Blaney S, Adamson P. Phase I trial and pharmacokinetic (PK) of lenalidomide (LEN) in pediatric patients with relapsed/refractory solid tumors or myelodysplastic syndrome (MDS): A Children's Oncology Group Phase 1 Consortium study. 2009 ASCO Annual Meeting. J Clin Oncol; 2009 May; 27(15S):abstr 10023.

2008

2008

ADVL0314 - Bevacizumab
Glade Bender JL, Adamson P, Reid JM, Xu L, Baruchel S, Shaked Y, Kerbel RS, Cooney EM, Stempak D, Chen HX, Nelson, Jr. MD, Krailo M, Ingle AM, Blaney S, Kandel J, Yamashiro D. Phase I trial and pharmacokinetic study of bevacizumab in pediatric patients with refractory solid tumors: A Children’s Oncology Group Study. J Clin Oncol; 2008 Jan; 26(3):399-405. PMID: 18202416.

ADVL0214 – Erlotinib
Jakacki R, Hamilton M, Gilbertson RJ, Blaney S, Tersak J, Krailo M, Ingle AM, Voss SD, Dancey JE, Adamson P. Pediatric Phase I and pharmacokinetic study of erlotinib followed by the combination of erlotinib with temozolomide: A Children’s Oncology Group Phase I Consortium study. J Clin Oncol; 2008 Oct; 26(30):4921-4927. PMCID: PMC2652086.

ADVL0011 – Temozolomide and Lomustine in HGGs
Jakacki R, Yates A, Blaney S, Zhou T, Timmerman RD, Ingle AM, Flom L, Prados MD, Adamson P, Pollack I. A Phase I trial of temozolomide and lomustine in newly diagnosed high-grade gliomas of childhood: A report from the Children's Oncology Group. Neuro-oncol; 2008 Aug; 10(4):569-576. PMCID: PMC2666230.

A09712 – Motexafin gadolinium
Bradley KA, Pollack I, Reid JM, Adamson P, Ames MM, Vezina G, Blaney S, Ivy SP, Zhou T, Krailo M, Reaman GH, Mehta M. Motexafin gadolinium and involved field radiation therapy for intrinsic pontine glioma of childhood: A Children’s Oncology Group Phase I study. Neuro-oncol; 2008 Oct; 10(5):752-758. PMCID: PMC2666252.

A0003 – Arsenic Trioxide in ALL
Fox E, Razzouk B, Widemann B, Goodspeed W, Reaman GH, Blaney S, Murgo A, Balis F, Adamson P, O'Brien M. Phase 1 trial and pharmacokinetic study of arsenic trioxide in children and adolescents with refractory or relapsed acute leukemia, including acute promyelocytic leukemia or lymphoma. Blood; 2008 Jan; 111(2):566-573. PMCID: PMC2200837.

0903 (CCG 0903) – Taxol (Paxlitaxel) in ALL
Horton TM, Ames MM, Reid JM, Krailo M, Pendergrass T, Mosher R, Reaman GH, Seibel N. A Phase I and pharmacokinetic clinical trial of paclitaxel for the treatment of refractory leukemia in children: a Children’s Oncology Group study. Pediatr Blood Cancer; 2008 Apr; 50(4):788-792. PMID: 17668866.

P9870 (POG-9870) – O6BG and BCNU
Adams DM, Zhou T, Berg S, Bernstein M, Neville KA, Blaney S. Phase 1 trial of O6-benzylguanine and BCNU in children with CNS tumors: a Children’s Oncology Group study. Pediatr Blood Cancer; 2008 Mar; 50(3):549-553. PMID: 17941066.

  Phase 1 Studies - Irinotecan Pharmacokinetics
Thompson PA, Gupta M, Rosner GL, Yu A, Barrett JS, Bomgaars L, Bernstein M, Blaney S, Mondick J. Pharmacokinetics of irinotecan and its metabolites in pediatric cancer patients: A report from the Children's Oncology Group. Cancer Chemother Pharmacol; 2008 Nov; 62(6):1027-1037. PMID 18278496.

ADVL0612 – Sunitinib Abstract
DuBois S, Shusterman S, Ingle AM, Baruchel S, Stempak D, Sun J, Ivy SP, Bender JG, Blaney S, Adamson P. A Pediatric Phase I Trial and Pharmacokinetic (PK) Study of Sunitinib: A Children’s Oncology Group Phase 1 Consortium Study. 2008 ASCO Annual Meeting. J Clin Oncol; 2008 May; 26(15S (May 20 suppl)):abstr 3561.

ADVL0517 – Ispinesib Abstract
Souid A, Dubowy R, Ingle AM, Sun J, Blaney S, Adamson P. Pediatric phase I trial and pharmacokinetic (PK) study of ispinesib (SB715992): A Children’s Oncology Group Phase 1 Consortium Study. 2008 ASCO Annual Meeting. J Clin Oncol; 2008 May; 26(15S (May 20 suppl)):abstr 10014.

ADVL0516 – Dasatinib Abstract
Aplenc R, Strauss LC, Shusterman S, Ingle AM, Agrawal S, Sun J, Wright JA, Blaney S, Adamson P. Pediatric phase I trial and pharmacokinetic (PK) study of dasatinib: A report from the Children’s Oncology Group Phase 1 Consortium. 2008 ASCO Annual Meeting. J Clin Oncol; 2008 May; 26(15S (May 20 suppl)):abstr 3591.

ADVL0416 – Vorinostat Abstract
Fouladi M, Park J, Sun J, Spiller SE, Ames MM, Stewart CF, Gilbertson RJ, Zwiebel J, Adamson P, Blaney S. A phase I trial and pharmacokinetic (PK) study of vorinostat (SAHA) in combination with 13 cis-retinoic acid (13cRA) in children with refractory neuroblastomas, medulloblastomas, primitive neuroectodermal tumors (PNETs), and atypical teratoid rhabdoid tumor. 2008 ASCO Annual Meeting. J Clin Oncol; 2008 May; 26(15S (May 20 suppl)):abstr 10012.

ADVL0319 – Lenalidomide Abstract
Russell HV, Cairo M, Blaney S, Adamson P, Ingle AM, Berg S. Phase I trial and pharmacokinetics (PK) of lenalidomide in pediatric patients with relapsed/refractory solid tumors or MDS: A Children's Oncology Group phase I consortium study. 2008 ASCO Annual Meeting. J Clin Oncol; 2008 May; 26(15S (May 20 suppl)):abstr 13532.

ADVL0319 – Lenalidomide Correlative Study Abstract
Ayello J, Berg S, Krailo M, van de Ven C, Lewis D, Harrison L, Blaney S, Adamson P, Cairo M. Lenalidomide (LMID) significantly enhances circulating serum levels of IL-2 and IL-15 levels, NK expansion and activation and NK and LAK cytotoxicity in children with refractory/recurrent solid tumors: A Children’s Oncology Group Phase I Consortium Report. 2008 ASH Annual Meeting Abstracts. Blood; 2008 Nov; 112(11):abstract 107.

ADVL0215 – Decitabine + Doxorubicin and Cyclophosphamide Abstract
George RE, Lahti J, Zhu K, Finkelstein JZ, Ingle AM, Reid JM, Krailo M, Neuberg D, Adamson P, Blaney S, Diller L. Decitabine in Combination with Doxorubicin and Cyclophosphamide in Neuroblastoma and other Solid Tumors - A Children’s Oncology Group Phase 1 Consortium Study. In: ANR 2008. Advances in Neuroblastoma Research 2008 Conference; 2008 May 21-24; Chiba, Japan.

ADVL0012 – Cereport (Labradimil) and Carboplatin Abstract
Packer R, Zhou T, Holmes E, Allen J, Jakacki RI. Timing, pattern of relapse and post-relapse survival in children with medulloblastoma: Results from four consecutive Children’s Oncology Group (COG) studies performed over the past twenty years. In: Abstracts from the Thirteenth International Symposium on Pediatric Neuro-Oncology; 2008 Jun 29–Jul 2; Chicago, IL. Oxford (England): Oxford University Press; 2008. p. 369-537. Neuro-oncol; 2008 Jun; 10(3):488.  

2007

2007

ADVL0411 - Temozolomide in ALL
Horton TM, Thompson PA, Berg S, Adamson P, Ingle AM, Dolan E, Delaney SM, Hedge M, Weiss HL, Wu M, Blaney S. A Phase I pharmacokinetic and pharmacodynamic study of temozolomide in pediatric patients with refractory/recurrent leukemia: A Children’s Oncology Group Study. J Clin Oncol; 2007 Nov; 25(31):4922-4928. PMID: 17971589.

ADVL0317 – Bortezomib in ALL
Horton TM, Pati D, Plon SE, Thompson PA, Bomgaars L, Adamson P, Ingle AM, Wright J, Brockman A, Paton M, Blaney S. A phase I study of the proteasome inhibitor bortezomib in pediatric patients with refractory leukemia: a Children's Oncology Group Study. Clin Cancer Res; 2007 Mar; 13(5):1516-1522. PMID: 17332297.

ADVL0316 – 17-AAG
Weigel BJ, Blaney S, Reid JM, Safgren SL, Bagatell R, Kersey J, Neglia J, Ivy SP, Ingle AM, Whitesell LJ, Gilbertson RJ, Krailo M, Ames MM, Adamson P. A phase I study of 17-allylaminogeldanamycin (17-AAG) in relapsed/refractory pediatric patients with solid tumors: a Children's Oncology Group study. Clin Cancer Res; 2007 Mar; 13(6):1789-1793. PMID: 17363534.

ADVL0311 – Pemetrexed
Malempati S, Nicholson HS, Reid JM, Blaney S, Ingle AM, Krailo M, Stork L, Melemed AS, McGovern R, Safgren SL, Ames MM, Adamson P. Phase I trial and pharmacokinetic study of pemetrexed in children with refractory solid tumors: a report from the Children’s Oncology Group. J Clin Oncol; 2007 Apr; 25(12):1505-1511. PMID: 1 17442992.

ADVL0211 – G3139
Rheingold S, Hogarty M, Blaney S, Zweibel J, Sauk-Schubert C, Chandula R, Krailo M, Adamson P. A phase I trial of G3139, a Bcl-2 antisense oligonucleotide, combined with doxorubicin and cyclophosphamide in children with relapsed solid tumors: a Children's Oncology Group study . J Clin Oncol; 2007 Apr; 25(12):1512-1518. PMID: 17442993.

ADVL0016 – Gefitinib Correlative studies
Jimeno A, Daw NC, Amador ML, Cusatis G, Kulesza P, Krailo M, Ingle AM, Blaney S, Adamson P, Hidalgo M. Analysis of biologic surrogate markers from a Children's Oncology Group Phase I trial of gefitinib in pediatric patients with solid tumors. Pediatr Blood Cancer; 2007 Sep; 49(3):352-357. PMID: 16425266.

ADVL0013 (CCG number-A0998) – 90Y-IT + Rituximab
Cooney-Qualter E, Krailo M, Angiolillo A, Fawwaz R, Wiseman GA, Harrison L, Kohl VK, Adamson P, Ayello J, van de Ven C, Perkins S, Cairo M. A phase I study of 90yttriumibritumomab-tiuxetan in children and adolescents with relapsed/refractory CD0-positive non-Hodgkin's lymphoma: a Children's Oncology Group study. Clin Cancer Res; 2007 Sep; 13(18 Pt 2):5652s-5660s. PMID: 17875803.

ADVL0516 – Dasatinib Abstract Aplenc R, Strauss LC, Shusterman S, Ingle AM, Luo R, Wright JE, Blaney S, Adamson P. Pediatric phase I trial and pharmacokinetic (PK) study of dasatinib: A report from the Children’s Oncology Group. In: 2007 ASCO Annual Meeting Proceedings Part I. J Clin Oncol; 2007 Jun; 25(18S):abstr 14094.

ADVL0416 – Vorinostat Abstract
Fouladi M, Park J, Sun J, Fraga C, Speights R, Ames MM, Stewart CF, Gilbertson RJ, Zweibel J, Adamson P, Blaney S. A phase I trial of vorinostat in children with refractory solid tumors: A Children's Oncology Group Study. In: 2007 ASCO Annual Meeting Proceedings Part I. J Clin Oncol; 2007 Jun; 25(18S):abstr 9569.

ADVL0415 – Oxaliplatin and Irinotecan Abstract
McGregor LM, Spunt SL, Furman WL, Stewart CF, Krailo M, Speights R, Houghton P, Ivy SP, Blaney S, Adamson P. A phase I study of oxaliplatin (OXA) and irinotecan (IRN) in pediatric patients with refractory solid tumors: a Children's Oncology Group study. In: 2007 ASCO Annual Meeting Proceedings Part I. J Clin Oncol; 2007 Jun; 25(18S):abstr 9546.

ADVL0414 – Vincristine + Irinotecan + Temozolomide Abstract
Perentesis J, Wagner LM, Ames MM, Reid JM, Stewart CF, Ingle AM, Blaney S, Adamson P. Phase I study of oral irinotecan, temozolomide, and vincristine for children with refractory solid tumors: a Children's Oncology Group study. In: 2007 ASCO Annual Meeting Proceedings Part I. J Clin Oncol; 2007 Jun; 25(18S):abstr 9563.

ADVL0215 – Decitabine + Doxorubicin and Cyclophosphamide Abstract
George RE, Lahti J, Ingle AM, Blaney S, Adamson P, Krailo M, Kidd VJ, Murgo A, Diller L. Decitabine (DAC) in combination with doxorubicin (DOX) and cyclophosphamide (CTX) in relapsed neuroblastoma (NBL): A Children’s Oncology Group Study. In: 2007 ASCO Annual Meeting Proceedings Part I. J Clin Oncol; 2007 Sep; 25(18S):abstr 9565.

2006

2006

ADVL0212 – Depsipeptide
Fouladi M, Furman WL, Chin TK, Freeman III BB, Dudkin L, Stewart CF, Krailo M, Speights R, Ingle AM, Houghton P, Wright J, Adamson P, Blaney S. Phase I study of depsipeptide in pediatric patients with refractory solid tumors: a Children's Oncology Group report. J Clin Oncol; 2006 Aug; 24(22):3678-3685. PMID: 16435380

ADVL0018 (CCG-A0981) – hu14.18-IL2
Osenga K, Hank JA, Albertini M, Gan JJ, Sternberg A, Eickhoff J, Seeger R, Matthay KK, Reynolds CP, Twist CJ, Krailo M, Adamson PC, Reisfeld R, Gillies SD, Sondel P. A phase I clinical trial of the hu14.18-IL2 (EMD 273063) as a treatment for children with refractory or recurrent neuroblastoma and melanoma: a study of the Children's Oncology Group. Clin Cancer Res; 2006 Mar; 12(6):1750-1759. PMCID: PMC2587020.

P9772 (POG-9772) – MGI 114
Bomgaars L, Megason GC, Pullen J, Langevin A, Weitman SD, Hershon L, Kuhn JG, Bernstein M, Blaney S. Phase I trial of Irofulven (MGI 114) in pediatric patients with solid tumors. Pediatr Blood Cancer; 2006 Aug; 47(2):163-168. PMID: 16317728.

CCG-09709 (POG-9709) – Fenretinide
Villablanca JG, Krailo M, Ames MM, Reid JM, Reaman GH, Reynolds CP. Phase I trial of oral fenretinide in children with high-risk solid tumors: a report from the Children's Oncology Group (CCG 09709). J Clin Oncol; 2006 Jul; 24(21):3423-3430. PMID: 16849757.

0936 (CCG-0936) – Vinorelbine
Johansen M, Kuttesch JF, Bleyer WA, Krailo MD, Ames MM, Madden T. Phase I evaluation of oral and intravenous vinorelbine in pediatric cancer patients: a report from the Children's Oncology Group. Clin Cancer Res; 2006 Jan; 12(2):516-522. PMID: 16428494.

ADVL0317– Bortezomib in ALL Abstract
Horton TM, Thompson PA, Bomgaars L, Adamson P, Krailo M, Ingle AM, Blaney S. A phase I study of bortezomib (PS-341) in pediatric patients with relapsed or refractory leukemia: a Children's Oncology Group study. In: 2006 ASCO Annual Meeting Proceedings Part I. J Clin Oncol; 2006 Jun; 24(18S (June 20 Supplement)):9021.  

ADVL0316 – 17-AAG Abstract
Weigel BJ, Blaney S, Kersey J, Bagatell R, Ivy SP, Whitesell LJ, Krailo M, Reid JM, Ames MM, Adamson P. A phase I study of 17-AAG in relapsed/refractory pediatric patients with solid tumors: a Children's Oncology Group Study. In: 2006 ASCO Annual Meeting Proceedings Part I. J Clin Oncol; 2006 Jun; 24(18S (June 20 Supplement)):9018.

ADVL0314 – Bevacizumab Abstract
Bender JG, Adamson P, Baruchel S, Shaked Y, Chen HX, Reid JM, Ingle AM, Blaney S, Kandel J, Yamashiro D. A phase I study of bevacizumab in children with refractory solid tumors: a Children's Oncology Group study. In: 2006 ASCO Annual Meeting Proceedings Part I. J Clin Oncol; 2006 Jun; 24(18S (June 20 Supplement)):9017.

ADVL0311 – Pemetrexed Abstract
Nicholson HS, Blaney S, Ingle AM, Krailo M, Stork L, Ames MM, Adamson P. Pediatric phase I study of pemetrexed: a report from the Children's Oncology Group. In: 2006 ASCO Annual Meeting Proceedings Part I. J Clin Oncol; 2006 Jun; 24(18S (June 20 Supplement)):9019.

ADVL0214 – Erlotinib Abstract
Jakacki R, Tersak J, Blaney S, Krailo M, Hamilton M, Dancey JE, Gilbertson RJ, Ingle AM, Adamson P. A pediatric phase I trial and pharmacokinetic (PK) study of erlotinib (ERL) followed by the combination of ERL with temozolomide (TMZ): a Children's Oncology Group Study. In: 2006 ASCO Annual Meeting Proceedings Part I. J Clin Oncol; 2006 Jun; 24(18S (June 20 Supplement)):9015.

ADVL0018 (CCG-A0981) – hu14.18-IL2 Abstract
Osenga K, Hank JA, Albertini M, Gan J, Sternberg A, Eickhoff J, Seeger R, Matthay KK, Reynolds CP, Twist CJ, Krailo M, Adamson P, Reisfeld R, Gillies SD, Sondel P. A phase I clinical trial of Hu14.18-IL2 (EMD 273063) as a treatment for children with refractory or recurrent neuroblastoma and melanoma: a study of the Children's Oncology Group. In: ANR 2006. Advances in Neuroblastoma Research 2006 Conference; 2006 May 17-20; Los Angeles, CA.

ADVL0013 (CCG number-A0998) – 90Y-IT + Rituximab Abstract
Cairo M, Cooney EM, Krailo M, Belanger R, Perkins S, Fawwaz R, Angiolillo A, Adamson P. Final results of a phase I study of (90)Y-Ibritumomab-Tiuxetan (90Y-IT) in children with recurrent/refractory CD20 positive lymphoma: A COG Phase I consortium study. In: Eleventh Conference on Cancer Therapy with Antibodies and Immunoconjugates; 2006 Oct 12-14; Parsippany, NJ.

2005

2005

ADVL0017 (CCG-A0972) – Flavopiridol
Whitlock J, Krailo M, Reid JM, Ruben S, Ames MM, Owen WC, Reaman GH. Phase I clinical and pharmacokinetic study of flavopiridol in children with refractory solid tumors: a Children's Oncology Group study. J Clin Oncol; 2005 Dec; 23(36):9179-9186. PMID: 16361620.

ADVL0016 – Gefitinib
Daw NC, Furman WL, Stewart CF, Iacono LC, Krailo M, Bernstein M, Dancey JE, Speights R, Blaney S, Reaman GH, Adamson P. Phase I and pharmacokinetic study of gefitinib in children with refractory solid tumors: a Children's Oncology Group study. J Clin Oncol; 2005 Sep; 23(25):6172-6180. PMID: 16135484.

ADVL0012 – Cereport (Labradimil) and Carboplatin
Packer R, Krailo M, Mehta M, Warren K, Allen J, Jakacki R, Villablanca JG, Chiba A, Reaman GH. Phase 1 study of concurrent RMP-7 and carboplatin with radiation therapy for children with newly diagnosed brain stem gliomas. Cancer; 2005 Sep; 104(6):1281-1287. PMID: 16078267.

A09717 (CCG-09717) – Thrombopoietin + G-CSF Following ICE
Angiolillo A, Davenport V, Bonilla M, van de Ven C, Ayello J, Militano O, Miller LL, Krailo MD, Reaman GH, Cairo MS. A phase I clinical, pharmacologic, and biologic study of thrombopoietin and granulocyte colony-stimulating factor in children receiving ifosfamide, carboplatin, and etoposide chemotherapy for recurrent or refractory solid tumors: a Children's Oncology Group experience. Clin Cancer Res; 2005 Apr; 11(7):2644-2650. PMID: 15814645.

P9972 (POG P9972) – Trabectedin
Lau L, Supko J, Blaney S, Hershon L, Seibel NL, Krailo MD, Qu W, Malkin D, Jimeno J, Bernstein ML, Baruchel S. A phase I and pharmacokinetic study of ecteinascidin-743 (Yondelis) in children with refractory solid tumors. A Children's Oncology Group study. Clin Cancer Res; 2005 Jan; 11(2 Pt 1):672-677. PMID: 15701855.

POG 9879 – Cyclosporine A, VP-16, Vcr + XRT in BSG
Greenberg M, Fisher PG, Freeman C, Korones DN, Bernstein ML, Friedman HS, Blaney S, Hershon L, Zhou T, Chen Z, Kretschmar CS. Etoposide, vincristine, and cyclosporin A with standard-dose radiation therapy in newly diagnosed diffuse intrinsic brainstem gliomas - a Pediatric Oncology Group phase I study. Pediatr Blood Cancer; 2005 Oct; 45(5):644-648. PMID: 16110498.

POG 9779 – Ralitrexed in ALL
Horton TM, Blaney S, Langevin A, Kuhn JG, Kamen BA, Berg S, Bernstein M, Weitman SD. Phase I trial and pharmacokinetic study of raltitrexed in children with recurrent or refractory leukemia: a Pediatric Oncology Group study. Clin Cancer Res; 2005 Mar; 11(5):1884-1889. PMID: 15756014.

ADVL0411 - Temozolomide in ALL Abstract
Horton TM, Dolan E, Hegdi M, Berg S, Adamson P, Blaney S. A phase I study of temozolomide (Temodar) in pediatric patients with relapsed or refractory leukemia. 2005 ASH Annual Meeting Abstracts. Blood; 2005 Nov; 106(11):abstract 4455.

ADVL0215– Decitabine + Doxorubicin and Cyclophosphamide Abstract
George RE, Medeiros-Nancarrow C, Adamson P, Blaney S, Kidd VJ, Lahti J, Krailo M, Look AT, Diller L. A phase I study of decitabine (DCT) in combination with doxorubicin (DOX) and cyclophosphamide (CTX) in the treatment of relapsed or refractory solid tumors – a Children's Oncology Group study. In: 2005 ASCO Annual Meeting Proceedings. J Clin Oncol; 2005 Jun; 23(16S, Part I of II (June 1 Supplement)):8530.

ADVL0212– Depsipeptide Abstract
Fouladi M, Furman WL, Chin TK, Freeman-Nord B, Stewart CF, Krailo M, Houghton P, Wright JE, Adamson P, Blaney S. A phase I trial of depsipeptide in children with refractory solid tumors: a Children's Oncology Group study. In: 2005 ASCO Annual Meeting Proceedings. J Clin Oncol; 2005 Jun; 23(16S, Part I of II (June 1 Supplement)):8528.

ADVL0211 – G3139 Abstract
Rheingold S, Krailo M, Blaney S, Hogarty M, Mascarenhas L, Adlard K, Barnich M, Murphy J, Chandula R, Adamson P. A phase I trial of G3139 (bcl-2 antisense) combined with cytotoxic chemotherapy in relapsed pediatric solid tumors – a Children's Oncology Group study. In: 2005 ASCO Annual Meeting Proceedings. J Clin Oncol; 2005 Jun; 23(16S, Part I of II (June 1 Supplement)):3102.

ADVL0017 (CCG-A0972) – Flavopiridol Abstract
Whitlock J, Krailo M, Reid JM, Ruben S, Ames MM, Owen WC, Reaman GH. Phase I clinical and pharmacokinetic study of flavopiridol in children with refractory solid tumors: a Children's Oncology Group study. Proc Amer Assoc Cancer Res; 2005 Apr; 46:1117, #4733.

ADVL0013 (CCG number-A0998) – 90Y-IT + Rituximab Abstract
Cairo M, Cooney EM, Krailo M, Belanger R, Perkins S, Fawwaz R, Angiolillo A, Adamson P. A phase I study of 90Y-ibritumomab-tiuxetan (90Y-IT) in children with recurrent/refractory CD20 positive lymphoma: a COG Phase I Consortium study. 2005 ASH Annual Meeting Abstracts. Blood; 2005 Nov; 106(11):abstract 2448.

2004

2004

ADVL0115 – Bortezomib
Blaney S, Bernstein ML, Neville KA, Ginsberg JP, Kitchen BJ, Horton TM, Berg SL, Krailo MD, Adamson P. Phase I study of the proteasome inhibitor bortezomib in pediatric patients with refractory solid tumors: a Children's Oncology Group study (ADVL0015). J Clin Oncol; 2004 Dec; 22(23):4804-4809. PMID: 15570082.

P9973 (POG-9973) – Imantinib in PH+ Leukemia
Champagne MA, Capedeville R, Krailo MD, Qu W, Peng B, Rosamilia M, Therrien M, Zoellner U, Blaney S, Bernstein ML. Imatinib mesylate (STI571) for treatment of children with Philadelphia chromosome-positive leukemia: results from a Children's Oncology Group phase I study. Blood; 2004 Nov; 104(9):2655-2660. PMID: 15231574.

P9870 (POG-9870) – O6BG and BCNU Pharmacokinetics
Neville KA, Blaney S, Bernstein ML, Thompson PM, Adams DM, Aleksic A, Berg SL. Pharmacokinetics of O(6)-benzylguanine in pediatric patients with central nervous system tumors: a Pediatric Oncology Group study. Clin Cancer Res; 2004 Aug; 10(15):5072-5075. PMID: 15297409.

9675 (POG-9675) – Tirapazamine and Cyclophosphamide
Aquino VM, Weitman SD, Winick N, Blaney S, Furman WL, Kepner JL, Bonate P, Krailo MD, Qu W, Bernstein ML. Phase I trial of tirapazamine and cyclophosphamide in children with refractory solid tumors: A Pediatric Oncology Group study. J Clin Oncol; 2004 Apr; 22(8):1413-1419. PMID: 15084615.

ADVL0018 (CCG-A0981) - hu14.18-IL2 Abstract
Osenga K, Hank JA, Albertini M, Gan JJ, Sternberg A, Seeger R, Matthay KK, Reynolds CP, Krailo M, Adamson P, Reisfeld R, Gillies SD, Sondel P. A phase I trial of immunocytokine HU14.18-IL2 in children with recurrent or refractory neuroblastoma and other GD2 positive malignancies: a study of the Children's Oncology Group. In: Abstracts for the 19th Annual Scientific Meeting of the International Society for Biological Therapy of Cancer; 2004 Nov 4-7; San Francisco, CA. Hagerstown (MD): Lippincott Williams & Wilkins; 2004. p. S1-S65. J Immunother; 2004 Nov; 27(6):S50.

ADVL0016 – Gefitinib Abstract
Daw NC, Furman WL, Stewart CF, Iacono LC, Krailo M, Bernstein M, Dancey JE, Blaney S, Adamson P. A phase I trial and pharmacokinetic study of gefitinib in pediatric patients with refractory solid tumors: a Children's Oncology Group study. In: 2004 ASCO Annual Meeting Proceedings (Post-Meeting Edition). J Clin Oncol; 2004 Jul; 22(14S (July 15 Supplement)):8522.  

ADVL0013 (CCG number-A0998) – 90Y-IT + Rituximab Abstract
Cairo M, Krailo M, Cooney EM, Harrison L, Perkins S, Fawwaz R, Belanger R, Wiseman GA, Adamson P, Griffin TC, Angiolillo A. Preliminary results of a phase I study of radioimmunotherapy with 90Y-ibritumomab-tiuxetan (90Y-IT) in children with refractory CD20-positive lymphoma: the Children's Oncology Group study ADVL0013. In: International Society of Paediatric Oncology, SIOP XXXVI Congress Meeting Abstracts. Pediatr Blood Cancer; 2004 Sep; 43(4, Supplement 6):332, #O.020.

ADVL0011 – Temozolomide and Lomustine in HGGs Abstract
Jakacki R, Prados MD, Yates A, Timmerman RD, Krailo M, Qu W, Adamson P, Pollack I. A phase I trial of temozolomide and CCNU in pediatric patients with newly diagnosed incompletely resected non-brainstem high-grade gliomas (HGG): a Children's Oncology Group study. In: Abstracts from the Eleventh International Symposium on Pediatric Neuro-Oncology. 2004 Jun 13–16; Boston, MA. Oxford (England): Oxford University Press; 2004. p. 401-470. Neuro-oncol; 2004 Oct; 6(4):459.

2003

2003

P9970 (CCG-P9970) – Cisplatin and Irinotecan
Souid AK, Dubowy R, Blaney S, Hershon L, Sullivan J, McLeod WD, Bernstein ML. Phase I clinical and pharmacologic study of weekly cisplatin and irinotecan combined with amifostine for refractory solid tumors. Clin Cancer Res; 2003 Feb; 9(2):703-710. PMID: 12576438.

POG 9670 – Rebeccamycin
Langevin, A.M., Weitman, S.D., Kuhn, J.G., Weintraub, S.T., Baruchel, S., Margolis, D., Furman, W., Bernstein, M., Blaney, S., Vietti, T. A phase 1 trial of rebeccamcycin analogue (NSC #655649) in children with refractory solid tumors: a Pediatric Oncology Group Study. J Ped Hematol Oncol, 25(7):526-533, 2003. PMID: 12847318.

POG 9573 – Taxol (Paclitaxel)
Hayashi RJ, Blaney S, Sullivan J, Weitman SD, Vietti TJ, Bernstein ML. Phase 1 study of Paclitaxel administered twice weekly to children with refractory solid tumors: a pediatric oncology group study. J Pediatr Hematol Oncol; 2003 Jul; 25(7):539-542. PMID: 12847320.

2002

2002

X0942 (CCG-0942) – Topotecan and Cisplatin
Wells RJ, Reid JM, Ames MM, Liu-Mares W, Krailo MD, Seibel NL, Mosher R, Reaman GH, Wiersma S. Phase I trial of cisplatin and topotecan in children with recurrent solid tumors: Children's Cancer Group Study 0942. J Pediatr Hematol Oncol; 2002 Feb; 24(2):89-93. PMID: 11990712.

POG 9579 - Doxil
Marina N, Cochrane D, Harney E, Zomorodi K, Blaney S, Winick N, Bernstein ML, Link M. Dose escalation and pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in children with solid tumors: a Pediatric Oncology Group study. Clin Cancer Res; 2002 Feb; 8(2):413-418. PMID: 11839657.

POG 9575 - Topotecan
Furman WL, Stewart CF, Kirstein M, Kepner JL, Bernstein ML, Kung F, Vietti TJ, Steuber CP, Becton D, Baruchel S, Pratt CB. Protracted intermittent schedule of topotecan in children with refractory acute leukemia: a Pediatric Oncology Group study. J Clin Oncol; 2002 Mar; 20(6):1617-1624. PMID: 11896112.

POG 9571 – Irinotecan Case report
Murry DJ, Cherrick I, Salama V, Berg S, Bernstein M, Kuttesch N, Blaney S. Influence of phenytoin on the disposition of irinotecan. J Ped Hem Onc; 2002 Feb; 24(2):130-133. PMID: 11990699.

2001

2001

POG 9571 – Irinotecan
Blaney S, Berg S, Vietti T, Pratt C, Hamre M, Dubowy R, Harris M, Weitman S, Sullivan J, Bernstein M. A phase I study of irinotecan in pediatric patients: a Pediatric Oncology Group study. Clin Cancer Res; Jan 2001; 7(1):32-37. PMID: 11205914.

NCTN_h_COLOR_Badge_180x60.png

 

 

 

   amazon smile donate